In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitors among patients with...

Full description

Bibliographic Details
Main Authors: Bowen Lou, Hui Liu, Yongbai Luo, Gulinigaer Tuerhong Jiang, Haoyu Wu, Chen Wang, Yue Wu, Bo Zhou, Zuyi Yuan, Jianqing She, Junhui Liu
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Lipids in Health and Disease
Subjects:
Proprotein convertase Subtilisin/kexin type 9 (PCSK9) inhibitors
Statin
Low density lipoprotein
Acute myocardial infarction
Online Access:https://doi.org/10.1186/s12944-022-01724-9

Internet

https://doi.org/10.1186/s12944-022-01724-9

Similar Items